ABSTRACT
To investigate the associatlon between thyroid dysfunction, thyroid autoimmunity and type 1 diabetes mellitus, a sample of 146 type 1 diabetic patients were studied. All referrals to diabetes clinic in diabetes research center were screened for TSH/T3 /T4 /T3Ru /HbA1c and Anti TO Ab, Anti Tpo Ab. For each patient, a questionnaire including variables such as time from diagnosis of Diabetes mellitus, age, gender, consumed hypoglycemic Drugs and type of diabetes were registered to determine association between thyroid dysfunction and each of these items. Of all the diabetic patients 37.7% was known to have thyroid dysfunction. The most common forms were: subclinical hypothyroidism% 13, hypothyroidism%8.9, hyperthyroidism%8.9, and subclinical hyperthyroidism%6.8. There was a significant difference between prevalence of thyroid dysfunction and gender [%40 of female,%30 of male, P=0.045]. A significant difference was found between age and thyroid dysfunction in type 1 diabetes mellitus [P=0.001]. There was no significant difference between HbA1c and Thyroid dysfunction. Positive TPo- Ab and TO- Ab were found in%60 and 42.90f patients respectively. There was a significant difference between time from diagnosis of diabetes mellitus [Type 1] and thyroid dysfunctions [P<0.05] Our prospective study confirms the association between thyroid dysfunction and type 1 Diabetes, and demonstrates the high prevalence of thyroid Auto Antibody in patients with type 1 Diabetes particularly women. We conclude that all patients with type 1 Diabetes mellitus should undergo annual screening with thyroid function tests
ABSTRACT
To evaluate bone mass in hypogonadal men who received testosterone, alendronate, calcium and vitamin D for one year. In this clinical trial 44 hypogonadal men were evaluated. For diagnosing of hypogonadism, serum LH, FSH, and testosterone levels of the patients were assessed using RIA method. Bone mineral density [BMD] was measured using dual energy x-ray absorptiometery [DXA] in lumbar spine [L2-L4] and femoral neck before treatment. All patients received 250 mg IM testosterone enanthate every 15-20 days. Patients with T score < -1.5 received 70 mg oral Alendronate weekly, testosterone, 1gr elemental calcium and 400 U vitamin D daily. Patients with -1.5 < T score < -1 received calcium and vitamin D supplementation and testosterone. After one year of treatment Bone mineral density was measured again. Results were compared with pretreatment BMD and the healthy age and sex matched control group. Serum testosterone level was measured again during the treatment. Forty four patients aged 18-57 years were included in this study. 25 of them completed the course of study after one year. The mean serum testosterone level was 0.5 +/- 0.5 ng/ml before the treatment. After one year, it increased to 5.5 +/- 3 ng/ml [PV=0.01]. The mean bone mineral density in lumbar spine was 0.97 +/- 0.22 g/cm[2] which differed significantly from the control group at baseline [1.017 +/- 0.12g/cm[2]] [PV=0.006]. After one year, the mean BMD increased to 1.09 +/- 0.22g/cm[2] [PV= 0.02], which showed no statistical significant difference with the control group [PV=0.13]. The mean baseline BMD in femoral neck was 0.88 +/- 0.12 g/cm[2], which showed no significant difference with the control group [0.92 +/- 0.10 g/cm[2]] [PV=0.45], the mean T score before treatment showed significant difference with the control group [PV=0.00]. Bone mineral density in femoral neck increased to 0.97 +/- 0.13 g/cm[2] after one year [PV=0.01]. The mean annual change of BMD in lumbar spine and femoral neck was 12 +/- 8.4% and 10 +/- 7.2% respectively during one year treatment. Annual change of BMD showed no significant difference in all types of hypogonadism after one year [PV=0.34]. There was no significant correlation between age and BMD level before treatment, BMD increment was higher in younger patients after treatment [PV=0.04]. The results show that one year administrating testosterone, alendronate, calcium and vitamin D in hypogonadal men can increase BMD significantly in lumbar spine and femoral neck
ABSTRACT
In different studies, the prevalence of metabolic syndrome outbreak has been reported as high as 7-43% among the women with polycystic ovary syndrome [PCOS]. This study was performed to determine the prevalence and predictors of the metabolic syndrome in PCOS women in Ahvaz. In an epidemiologic descriptive study, a total number of 53 women who attended the endocrinology clinic in Ahvaz from 2007 through 2008, and were diagnosed as PCOS, according to the Rotterdam criteria, were enrolled in the study. The prevalence of metabolic syndrome was studied on the basis of the criteria explained by American National Cholesterol Panel [ATP-III criteria] Fifty three women with the mean age of 24 +/- 6.8 years were studied in this research. Prevalence of metabolic syndrome in women of Ahvaz was estimated to be as 13.5%, and the prevalence for individual components comprising the metabolic syndrome were: fasting glucose blood concentrations greater than or equals to 110 mg/dl in 4 patient [7.7%], hypertension in 4 patients [7.7%], waist circumference greater than or equals to 88 cm in 14 patients [34.1%], HDL less than 40 mg/dl in 12 patients [24%], triglyceride greater than or equals to 150 mg/dl in 5 patients [9.4%], IFG in 17 patients [32.7%], diabetes in 3 patients [5.8%] and dislipidemia in 31 patients [60%]. The Metabolic Syndrome and its elements occur frequently in women with PCOS that places them at risk for cardiovascular diseases, therefore screening for these disturbances is recommended